Proffitt & Goodson’s aTyr Pharma ATYR Stock Holding History

Proffitt & Goodson’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-880	Closed	-$4.46K	–	453
2025 Q2	$4.46K	Buy	+880	New	+$3.46K	﹤0.01%	233

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Proffitt & Goodson's ATYR Position: Q3 2025 in Review

Proffitt & Goodson sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 880 shares — an estimated $4.46K sold.

Proffitt & Goodson first reported a position in ATYR in Q2 2025 and held it in 1 quarter. The position peaked at $4.46K in Q2 2025. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.

Proffitt & Goodson reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
Proffitt & Goodson sold 880 aTyr Pharma shares in Q3 2025, an estimated $4.46K.
Proffitt & Goodson first reported a position in aTyr Pharma in Q2 2025 and held it in 1 quarter.
Proffitt & Goodson's aTyr Pharma position peaked at $4.46K in Q2 2025.
103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.

Based on Proffitt & Goodson's 13F filing for Q3 2025, filed 21 Oct 2025.